Category Archives: Stem Cell Clinic


Growing Focus on Product Innovation Likely to Impact the Growth of the Animal Stem Cell Therapy Market 2017 2025 – Cole of Duty

A new intelligence report Animal Stem Cell Therapy Market has been recently added to Adroit Market Research collection of top-line market research reports. Global Animal Stem Cell Therapy Market report is a meticulous all-inclusive analysis of the market that offers access to direct first-hand insights on the growth trail of market in near term and long term. On the basis of factual information sourced from authentic industry experts and extensive primary industry research, the report offers insights on the historic growth pattern of Animal Stem Cell Therapy Market and current market scenario. It then provides short- and long-term market growth projections.

Projections are purely based on the detailed analysis of key market dynamics that are expected to influence Animal Stem Cell Therapy Market performance and their intensity of impacting market growth over the course of assessment period.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/14941

In addition to evaluation of dynamics, the report provides in-depth examination of key industry trends that are expected to act more prominently in global Animal Stem Cell Therapy Market. The study also offers valued information about the existing and upcoming growth opportunities in Animal Stem Cell Therapy Market that the key players and new market entrants can capitalize on.

Competitive companies and manufacturers in global market

Key Participants

The key participants in the animal stem cell therapy market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and Clinic Frisco, CO, etc. The companies are entering into the collaboration and partnership to keep up the pace of the innovations.

The report covers exhaustive analysis on:

Regional analysis for Market includes

Report Highlights:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/14941

Opportunity assessment offered in this Animal Stem Cell Therapy Market report is important in terms of understanding the lucrative areas of investment, which prove to be the actionable insights for leading market players, suppliers, distributors, and other stakeholders in Animal Stem Cell Therapy Market.

In-depth global Animal Stem Cell Therapy Market taxonomy presented in this report provides detailed insights about each of the market segments and their sub-segments, which are categorized based on t par various parameters. An exhaustive regional analysis of global Animal Stem Cell Therapy Market breaks down global market landscape into key geographies.

Regional outlook and country-wise analysis of Animal Stem Cell Therapy Market allows for the evaluation of multi-faceted performance of market in all the key economies. This information intends to offer a broader scope of report to readers and identify the most relevant profitable areas in global market place.

Key Regions and Countries Covered in Global Animal Stem Cell Therapy Market Report-

Taxonomy and geographical analysis of the global Animal Stem Cell Therapy Market enables readers to spot profits in existing opportunities and capture upcoming growth opportunities even before they approach the market place. The analysis offered in report is purely intended to unroll the economic, social, regulatory and political scenarios of the market specific to each region and country, which could help potential market entrants in Animal Stem Cell Therapy Market landscape to understand the nitty-gritty of target market areas and devise their strategies accordingly.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/14941

Animal Stem Cell Therapy Market Table of Contents

See the original post here:
Growing Focus on Product Innovation Likely to Impact the Growth of the Animal Stem Cell Therapy Market 2017 2025 - Cole of Duty

Facial Injectable Market Growth Analysis, Size Projection, Key Insights, COVID-19 Impact Analysis and Future Trends By 2025 – Cole of Duty

Global Facial Injectable Market Share, Growth and Trends Analysis by Type (Botulinum Toxin, Hyaluronic Acid, Polymers and Particles and Collagen), Application (Facial Line Correction Treatment, Face Lift and Lip Treatments), End User (Hospitals, Specialty Clinics and Spa & Beauty Clinic) and Region (North America, Europe, Asia-Pacific and Middle East & Africa) Forecast till 2025

Anti-ageing, face rejuvenation and cosmetic treatments have changed the rules of engagement and reinvention. Today, its possible to change the basic elements of yourself to fulfil the basic desire of humans to be young.

Thefacial injectable marketis been driven by numerous factors. However rising proportion and absolute numbers of older people led by baby boomers generation with good incomes are the critical driving factor for the global facial injectable market. According to the World Health Organization estimates between 2015 and 2050, the proportion of the worlds population over 60 years will double from 12% to 22% which will be a positive development for the market.

Another critical driver and the motive behind the market is the primal desire to remain young. The extension of life has been a primal desire of humanity and a mainstay motif in the history of scientific pursuits and ideas throughout history, from the Egyptian Smith medical papyrus, Ayurveda practitioners, alchemists, etc. This primal desire for youth has driven the market for anti-ageing drugs since time immemorial.

Request Free Sample Copy at:https://www.marketresearchfuture.com/sample_request/1527

The growing influence of lifestyle, fashion and film industry have led to rising demand of medications to slow the ageing and its signs. Health and youth wellness have become a status symbol and youthful appearance is penetrating peoples life and there is increasing consumerization of youth. The growth of media such as television and lifestyle magazines have led to a craze for youthful appearance.

Other driving factors are primal desire of humans to remain young, influence of lifestyle industry and rising awareness about wellbeing, high levels of disposable incomes etc. The market restraints are skepticism and concerns of safety regarding the unrestricted use of anti-ageing drugs without greater and clearer experimental validation. Ambiguity of the definition of anti-ageing drugs is also a cause of concern. For example, numerous cosmetics have been included or claimed to have anti-aging effects and have been termed as Cosmeceuticals. Cosmeceutical is defined by the cosmetic industry as cosmetic products that have medicinal or drug like effects which is not supported by the U.S. Food and Drug Administration (FDA) or the Food, Drug and Cosmetic Act.

The facial injectable market is a technological oriented market having a high research and development potential due to advancement in technologies and cellular understanding which are keys to unravel the exact mechanism of ageing. Gene therapy, stem cell technology and targeted delivery of nutrients using biotechnology are expected to open the gates for anti-ageing drugs. The development of biomarkers for physiochemical modifications in the body such as alteration of concentration of an enzyme or hormone provides another exiting avenue for the future market. For example, levels of homocysteine has been proposed as a marker of age related changes in the body so as to compensate the change by drugs.

From a market perspective the facial injectable market is ripe with mergers, acquisitions and partnerships. For example, in 2017, cosmetic giant LOral acquired skincare brands such as CeraVe, AcneFree and Ambi from Valeant Pharmaceuticals at ~ $1.25 billion. In 2016, Johnson & Johnson acquired Vogue International LLC, for greater than $3 billion to strengthen its consumer segment. Thus, partnerships seem to be a good strategy to curtail the developmental cost of any new facial injectable drug. Acquisition of other companies also leads to expansion of product lines which improves market penetration and exposure.

The global market for facial injectable is expected to reach USD 9.04 billion by the end of the forecasted period 2023 and is expected to grow at a CAGR of 13.2%

Global facial injectable market is segment by types and applications. Based on types the market is sub-segmented as botulinum toxin, hyaluronic acid, polymers & particles, and collagen. On the basis of application, the market is sub-segmented into facial line correction treatment, face-lift, lip treatments and others.

The key players in his market are Allergan, Galderma, Integra Lifesciences, Merz Pharma, Sanofi, SciVision Biotech Inc, Sinclair. Suneva Medical and Valeant Pharmaceuticals.

Regional outlook for the facial injectable market

The facial injectable market is dominated by North America. The U.S. is the prime mover of the facial injectable market. However, it has to be noted that Latin America despite its lower per capita income has a disproportionate share of the market. It is estimated that Latin America will be the fastest in the future. As of the present the European regions is expected to be the second largest market globally, with countries like Germany, UK and France playing a prominent role in the market. Germany accounts for both the largest and the fastest growing nation in the European region facial injectable market, followed by France.

Asia Pacific market is expected to be the fastest future growing market during the forecast period 2016-2023. The Asia Pacific region will be led by countries such as China and India. However the greatest hindering reasons for the Asia pacific region market is the poor per capita income and the high cost of treatment. Nations such as Thailand etc. have a disproportionate share of Asia Pacific market considering their low income as compared to the U.S. The market of these nations is influenced to a considerable degree by the tourism and fashion industry. Advertisement and greater exposure seems to be the best strategy to be a market leader along with product development. The return on investment for advertisement and publicity is very high for the cosmetic surgery market.

There has been a definite shift of the cosmetic surgery market from the developed regions to the developing ones particularly Latin America and Asia Pacific countries such as Thailand. The market represents a clustered outlook with urban metropolitan cities especially with adjoining tourism and fashion industry having an extreme lead over the rural areas. Large tourism clusters such as Miami, Bangkok, Bali etc. have a disproportionate share of the market due to the large volume of cosmetic surgeries.

The porn industry also is affecting the market and it has been seen that the rise of cosmetic surgeries has a linear relationship with the quality and bandwidth of the internet. Thus cities such as Los Angeles, Las Vegas etc. are the leading clusters of cosmetic surgery market.

Browse Complete Research Report with COVID-19 Impact Analysis at:https://www.marketresearchfuture.com/reports/facial-injectable-market-1527

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [emailprotected]

More here:
Facial Injectable Market Growth Analysis, Size Projection, Key Insights, COVID-19 Impact Analysis and Future Trends By 2025 - Cole of Duty

Another four biotechs scratch out the first number and ask for more as IPO boom continues – Endpoints News

Four more biotechs are raising their offers in an already record year for biotech IPOs.

Softbank-backed Relay Therapeutics scratched out its original $200 million filing and proposed a $250 million raise that would make them a $1.5 billion company. CAR-T developer Poseida Therapeutics bumped itself up $74 million to $224 million. Off-the-shelf cell therapy startup Nkarta upped from $150 million to $215 million and then priced even higher, at $252 million. Frances Inventiva did its own modest reset, raising its bar from $102 million to $108 million.

Poseida, Nkarta and Inventiva priced today. Relay will price next week.

Barring a surprise flop, the latest flurry of raisesmeans there will be 13 $200 million-plus biotech IPOs in 2020 before August. By contrast, all of 2019 saw two biotechs pass that mark; 2018 saw 7 do so.

The run of eye-catching deals began in the first days of April when, after a pair of pandemic-driven stock market crashes, the small and little-known biotech Zentalis managed to score $165 million in a public offering. At the time, Nasdaqs Jordan Saxe told Bloomberghe expected biotech to open the IPO market back up, with its investors more focused on the long term than a short term that had the potential to be brutal. He predicted 30-35 IPOs for $3.5 billion and a series of blank check companies, a pair of predictions that have since looked prescient.

Its not just private companies that are getting in on the action. Public biotechs, too, have put out for large raises. This week alone Vir Biotechnology offered $300 million in a secondary offering, Revolution Medicines offered $156 million and Akero Therapeutics offered $188.2 million.

The buzz has allowed, among other things, very early stage companies to attract significant interest, including a single week in June when three preclinical biotechs raised over $200 million in a single week.

That trend has continued into this week. Nkarta, focused on natural killer cell therapies, has yet to bring a candidate into the clinic, although they plan to do so later this year. Relay Therapeutics, focused on solid tumors, only started their first trial earlier this year.

Poseida and Inventiva, though, are further along. With backing from Novartis, Poseidas BCMA CAR-T is already in Phase II and, earlier this year, they started recruiting for a Phase I with another CAR-T therapy. Inventiva is in Phase II for a NASH drug and a mucopolysaccharidosis type VI drug.

Read more:
Another four biotechs scratch out the first number and ask for more as IPO boom continues - Endpoints News

Props to You, Californians: A Preview of What’s on Your November Ballot – gvwire.com

This past week marked the deadline for citizens and special interests to snag their spot on the November ballot. (AP File)

After a bit of last-minute legislative maneuvering, the list of propositions that California voters will be asked to weigh in on has been more or less finalized.

Ben Christopher

CalMatters

This past week marked the deadline for citizens and special interests to snag their spot on the Nov.3 ballot. Eight measures made the cut. They address matters as vital and/or esoteric as rent control, property tax law, dialysis clinic staffing requirements, stem cell research funding and the preservation or final dispatch of cash bail in California.

The same date also marked the deadline for legislators to place their preferred measures on the November ballot. But lawmakers have a bit more flexibility when it comes to deadlines.This flexibility gave lawmakers a few extra hours to add four measures: two to expand voting rights, one that ends a 22-year-old ban on affirmative action, and one that is a tortuously complicated property tax measure that somehow ropes in Realtors, wildland firefighters and The Dude from The Big Lebowski.

Heres your November ballot preview:

These three measures, all placed on the ballot by the Legislature, had been introduced before protests against racism and police brutality swept the country. But as California lawmakers look for ways to play a role in the national debate about institutional barriers to equity and the meaning of citizenship, many legislators see these as particularly potent causes.

Ending the ban on affirmative action

Who put it there: The Legislature, via abillby San Diego Democrat Assemblymember Shirley Weber

Type: Constitutional amendment

What it would do: Allow schools and public agencies to take race and other immutable characteristics into account when making admission, hiring or contracting decisions.

In 1996 California voters passedProposition 209, a constitutional amendment banning affirmative action at state institutions. The result was an immediate drop in Black and Latino enrollment at the states elite public universities. Some civil rights organizations have been trying to repeal Prop. 209 ever since.

Each of those attempts has been stymied by a coalition of Republicans, moderate Democrats and some progressive legislators who represent districts with large Asian American voting populations. This year, as in previous years, some of the most vocal and persistent opponents of the effort to reintroduce affirmative action have beenChinese-American political activists. They argue that boosting enrollment of students from underrepresented racial groups would come at the expense of overrepresented Asian American students.

Restoring the right to vote to people on parole

Who put it there: The Legislature, via abillby Sacramento Democrat Assemblymember Kevin McCarty.

Type: Constitutional amendment

What it would do:Allow Californians who are currently on parole to vote.

In 1974, California voters passed a ballot measure giving people who have committed felonies the right to vote once they complete their sentences and are no longer on parole.

Thanks to that law, there are some 40,000 Californians who are not in prison but unable to legally cast a ballot. But as with any criminal justice debate, this is also one about race. According to anestimate from 2016, two thirds of people on parole in the state are Latino or Black.

Letting (some) 17-year-olds vote (some of the time)

Who put it there: The Legislature, with abillintroduced by San Mateo Democrat Assemblymember Kevin Mullin.

Type: Constitutional amendment

What it would do: Allow 17-year-old U.S. citizens to vote in a primary and special election as long as they will turn 18 by the subsequent general election.

California Democrats have been on a decade-long tear increasing voting access. Same-day voter registration, automatic registration at the DMV and pre-registration of 16- and 17-year-olds are among the recent pro-vote innovations to come out of the Capitol.

Letting people under 18 vote would be yet another extension. Already 23 states let 17- year-olds vote in certain circumstances.

Democratic legislators have tried to do this six times before; this is the first to make the ballot.

This wouldnt be a California election without at least a few wildy contentious ballot measures about housing and property taxes.

Split roll

Who put it there: Citizens. Campaign largely funded by the California Teachers Association, SEIU California and the Chan Zuckerberg Foundation

Type: Constitutional amendment

What it would do:Tax some commercial property based on its market value, rather than the price at which it was purchased. This would raise property taxes on many large businesses across the state, increasing funding for schools and local government.

In 1978, California voters passed Proposition 13, placing a cap on property taxes, kicking off a nationwide anti-tax revolt and placing city and county budgets in a generation-spanning straitjacket.

By tying a landlords property tax payments to the original purchase price, Prop. 13 has been thegift that keeps on givingto property owners, particularly those lucky enough to have bought cheap real estate decades ago. Theres been bipartisan reluctance among lawmakers to touch it ever since, lest they incur the wrath of irate homeowners.

This initiative attempts to divide and conquer that political problem by repealing the property tax protections only for commercial landlords with more than $3 million in holdings. If this measure passes, those landowners would have to make tax payments based on the current value of their properties a tax hike for most resulting in anestimated$6.5 to $11.5 billion more for cities, counties and school districts.

Property tax breaks and closing the Lebowski loophole

Who put it there: The Legislature, via abillby San Mateo Democrat Assemblymember Kevin Mullin, but sponsored by the California Realtors.

Type: Constitutional amendment

What it would do: Allow homeowners who are over 55, disabled or victims of natural disaster to take a portion of their property tax base with them when they sell their home and buy a new one. It would also limit the ability of new homeowners who inherit properties to keep their parents or grandparents low property tax payments. Most of the additional money raised would go into a state fire response fund.

Weve seen this one before half of it, anyway. In 2018, the California Association of Realtors put ameasure on the ballotallowing older or disabled homeowners to keep a portion of their Prop. 13 tax break. The Realtors argued that the current property tax rules disincentivize longtime homeowners from moving, trapping empty-nesters in houses that are too big for them and locking out new families. But because the measure would cost schools, counties and cities, it was opposed by organized labor and local government groups and failed by 20 points.

The Realtors tried again this year, but with an added fiscal sweetener. Under this proposal, anyone who inherits a home from their parents or grandparents would only be allowed to keep the low property taxes if they use the home as their primary residence and only on the first $1 million between the homes original purchase price and its market value. Inspiration for that caveat may have come from theLos Angeles Times, which tracked down a number of California scions, including The Big Lebowski star Jeff Bridges, who are still paying 1970-era property tax levels on their rental properties.

And then there was a last-minute wrinkle. In the final weeks of June, the Realtors sprang a deal: designating that most of the funding generated by the measure would go to fighting wildfires. That won the support of the influential California Professional Firefighters union. It also means the measure will be funding a public need that might be on many voters minds come November.

That bargain was struck after the Realtors had submitted their signatures, so with the help of Assemblyman Mullin, they passed it through the Legislature, pulling their original proposal just before the deadline.

Rent Control (Again)

Who put it on the ballot: Signatures, collected via an effort mostly funded by the AIDS Healthcare Foundation.

Type: Statute

What it would do: Allow cities to introduce new rent control laws, or expand existing ones.

Despite a 20-percentage point, 56-out-of-58 county defeat in 2018, a statewide rent control measure is back on the ballot.

Polling from that election seasonsuggestedthat California voters generally liked rent control as a concept, but worried about the specifics of the proposal. Accordingly, this new initiative makes a few tweaks.

Under this one, cities would be allowed to apply new rent control ordinances only to homes that are at least 15 years old. And it exempts single-family homes owned by landlords with no more than two properties.

Just like last time, the measure is being pushed by the Los Angeles-based AIDS Healthcare Foundation and its pugnacious presidentMichael Weinstein. State lawmakers by passing a law last year that set a7% ceilingon how much landlords can raise rents each year had hoped to ward off another attempt by Weinstein and company. They had no such luck.

(Shutterstock)

California, the home of three-strikes sentencing, has spent the last decade rethinking its approach to criminal justice. Two measures on the November ballot, channeling the spirit of the 90s, are pushing to reverse that reversal.

Ditch or keep cash bail

Who put it there: Signatures, via a campaign largely funded by the bail bond industry.

Type: Referendum

What it would do: Ask voters to either approve or strike down a state law that banished money bail from the state criminal justice system.

In 2018, acting on the advice of state Supreme Court Chief Justice Tani Cantil-Sakauye, legislators passed a billending cash bail in California. Rather than letting people pay their way out of jail while they await trial, the law gives judges the right to determine whether someone who is arrested should be kept behind bars based on the risk they are deemed to pose to themselves or others.

Moving quickly, the bail bond industry mounted a campaign to put the question on the ballot as a referendum. Voters will vote either Yes to keep the state law and end cash bail for good, making California the first state to do so, or No to keep the bail system.

Rolling back Brown-era leniency

Who put it there: Signatures, via a campaign largely funded by law enforcement agencies.

Type: Constitutional amendment

What it would do: Allow prosecutors to charge repeat or organized petty theft as a felony, require probation officers to seek tougher penalties for those who violate the term of their parole three times, and exclude those who have been convicted of domestic violence and certain nonviolent crimes from early parole consideration.

Gov. Jerry Brown was famously allergic to talk of his legacy while in office. But if the former governor has one, it might be the effort he spent in his final two terms as governor supporting efforts to reverse the tough on crime policies he helped introduce during his first two terms in the 1970s and 80s.

In 2011, California legislators reduced punishments for parole violators. In 2014, voters passed Proposition 47, recategorizing some non-violent crimes as misdemeanors. In 2016, voters passed Proposition 57, giving inmates convicted of certain non-violent offenses a shot at early release.

This ballot measure would partially undo each of those.

Usually standoffs between employees and their bosses take place behind closed doors. In California, you often find them on the ballot.

Self-employment for ride-hail and other app-drivers

Who put it there: Signatures, via a campaign mostly funded by Lyft, Uber and Doordash

Type: Statute

What it would do: Turn app-based drivers into independent contractors, exempting companies such as Lyft and Uber from standard wage and hour restrictions. It would also guarantee these drivers an earnings floor, a stipend to purchase health insurance and other minimum benefits.

Unless you happen to be ananti-vaccine protestor, the most controversial law of the 2019 legislative session wasAssembly Bill 5. On its face, the law simply codified a state Supreme Court ruling, making it much harder for companies to treat their workers as independent contractors, rather than full-fledged employees. In practice, it upended the business models of Uber, Lyft, Doordash, Postmates and Instacart, all of which rely on an army of phone-toting gig-workers to provide their various services.

In the months since, all attempts at legislative compromise have fizzled, Californias Attorney General hassued Uber and Lyftfor violating the new law and California regulatorsdeclaredtheir drivers to be employees.

As a last-ditch effort, the various companies implicated have poured $110 million and counting to push a ballot measure that would simply exclude their drivers from the law. And throwing a bone to critics who say their drivers are mistreated, the measure also imposes some worker benefits and protections.

Regulating dialysis clinics

Who put it there: Signatures, via an effort funded entirely by the Service Employees International Union-United Healthcare Workers West

Type: Statute

What it would do: Require dialysis clinics to have at least one physician on site at all times and to report patient infection data to California health officials.

DaVita Kidney Care and Fresenius Medical Care own the majority of the for-profit dialysis clinics in the state. For years, the Service Employees International Union-United Healthcare Workers union has been at war with them.

After unsuccessful efforts to unionize clinic staff, the union sponsored legislation to cap reimbursement rates to clinics and floated an array of possible ballot measures to boost their staff spending and cut their profits. In 2018, the union finally got one on the ballot:Prop 8, which would have set a cap on clinic profit margins.

The measure was soundly defeated, but only after the two companies spent over $111 million, making it the most expensive ballot campaign ever. This one isnt likely to be much cheaper.

FILE In this Jan. 12, 2016, file photo, a ride share car displays Lyft and Uber stickers on its front windshield in downtown Los Angeles. Law enforcement agencies and ride-hailing companies are intensifying efforts to warn passengers against getting in without checking to ensure both the vehicle and driver are legitimate. (AP Photo/Richard Vogel, File)

Two measures on this years ballot aim to bolster laws and programs already on the books. Both campaigns are led by Bay Area real estate developers with a penchant for ballot box policymaking.

Stronger consumer privacy laws (again)

Who put it there: Signatures, via a campaign funded entirely by Alastair and Celine Mactaggart.

Type: Statute

What it would do: Strengthen Californias already strongest-in-the-nation consumer privacy law and establish a California Privacy Protection Agency

In 2018, California lawmakers passed theCalifornia Consumer Privacy Act, giving consumers the right to find out what data companies are collecting about them, to opt out of having it collected and to have that data scrubbed. It was and remains the only law like it in the county. It was also acompromise. San Francisco real estate developer Alastair MacTaggart had been pushing for an even stricter ballot measure, but the Legislature stepped in, brokering a deal between MacTaggart and the tech industry.

Now MacTaggart is back. Along with setting up a state agency tasked with enforcing state privacy law, the measure would beef up financial penalties for violators and allow consumers to demand that personal information not be shared at all, rather than simply not sold.

Borrowing for stem cell research

Who put it there: Signatures via an effort mostly funded by Robert Klein, JDRF International and Open Philanthropy

Type: Bond

What it would do: Borrow $5.5 billion to fund stem cell research

In 2004, voters passed Proposition 71 to create the California Institute for Regenerative Medicine. The institute exists to channel state money toward stem cell research. Prop 71 also let the state borrow $3 billion to do that.

That pot of cash is now almost empty. Robert Klein, a Silicon Valley real estate developer who led the Prop. 71 effort and became the institutes first board chair, is leading the campaign for more.

2020 ElectionCalifornia votersGov. Gavin Newsom

Originally posted here:
Props to You, Californians: A Preview of What's on Your November Ballot - gvwire.com

Goal of Plentiful Organ Transplants Moves Closer to Reality as Scientists Grow Tiny Working Livers from Skin Cells – Good News Network

As reported in an eye-opening new research paper, scientists have created tiny human livers out of human skin cells before successfully transplanting them into rats.

What we are planning to do is to start making mini human organs that are universal, explained the papers co-author, Alejandro Soto-Gutirrez, from the University of Pittsburgh.That would change the paradigm of transplants.

The science-fiction-like procedure was done by taking adult skin cells and genetically altering certain genes and transcription factors to create what are known as pluripotent stem cells.

It starts with human skin cells called fibroblasts, in 2006 the pioneering field of genetic-editing led scientists to discover that they can simply take any cell from a living adult and turn it into a pluripotent stem cell.

Pluri, meaning plurality, indicates its ability to carry the genetic code of all organ types, which is how they can become liver cells.

RELATED: For the First Time in the US, Surgeons Pump New Life into Dead Donor Heart for Life-Saving Transplant

According to the Mayo Clinic, the number of people on current waiting lists for liver transplants far exceeds the number of available liver donors. The cost is just as high: the medical journal Inverse reports the average cost of a transplant, accounting for the entire procedure, is about $812,000.

New technologies always reduce the cost of existing products (remember how expensive flat screen televisions were?) and a new paradigm of made-to-order fabrication of organs would likely fulfill all the demand for transplants while lowering the cost at the same time.

As fascinating as it is a little unsettling, the science took a decade to perfect, but is far still from human trials. The tiny organs from human cells continued working normally after they were transplanted into rats bred to have suppressed immune systems otherwise the body would reject the foreign organ.

RELATED: Game-Changing Approval of Liver Transplant Procedure Expected to Halve the Waiting List

The method and associated technology could produce part-time liver grafts, that could prolong the lives of people waiting on the transplant list.

The long-term goal is to create organs that can replace organ donation, but in the near future, I see this as a bridge to transplant, Soto-Gutirrez told Inverse. For instance, in acute liver failure, you might just need a hepatic boost for a while, instead of a whole new liver.

(File photo by OPCW Laboratory in Rijswijk, CC license)

YOUR Friends May Be On The Waiting List For Good NewsShare on Social Media

Visit link:
Goal of Plentiful Organ Transplants Moves Closer to Reality as Scientists Grow Tiny Working Livers from Skin Cells - Good News Network

Vor bags $110M to move engineered cell therapy into the clinic – FierceBiotech

CAR-T treatments and other immunotherapies have changed the treatment of some blood cancers, but they can target healthy cells as well as cancer cells, causing nasty side effects. Vor Biopharma is working on an engineered stem cell solution, and its raised $110 million to move its lead program into the clinic.

The Cambridge, Massachusetts-based company is developing the treatment, VOR33, for patients with acute myeloid leukemia (AML) whose disease has worsened despite undergoing chemotherapy or a stem cell transplant.

Thats the setting in which a lot of targeted agents are used. The trouble is, a great number of the targeted agents tend to failnot because they are not efficacious, but because the drug is too toxic for the patients bone marrow, Vor CEO Robert Ang told Fierce Biotech.

Submit your entry to demonstrate innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies.

The drugs home in on healthy cells as well as cancerous ones because they express the same proteins. This leads to myelosuppression, which means the bone marrow doesnt make enough white blood cells, platelets or red blood cells for the patient to survive, Ang said.

RELATED: Neon CBO Robert Ang jumps ship to take the helm at Vor Biopharma

Vors treatment is made from hematopoietic, or blood-forming, stem cells from healthy donors. The company uses gene editing to get rid of cancer drug targets in those cells that are biologically redundant, which means deleting them doesnt cause any harm. That target is CD33, in the case of VOR33.

Were trying to make the marrow treatment resistant such that the only cells that are expressing CD33 should be cancer cells, Ang said. We should be able to target them much more specifically, while minimizing the collateral damage that typically happens with these drugs.

RELATED: 5AM, JJDC get in on $42M series A round for cell therapy player Vor Biopharma

Vor believes its treatments could boost the reach of targeted therapies by improving their efficacy and increasing the amount of time patients can undergo those treatments.

And thats not all. In addition to protecting these transplants and the blood cells they produce from targeted drugs, Vor thinks its approach could change the way we think about bone marrow transplant.

To some degree, transplants have been relatively decentralized and less controlled A lot of hospitals develop their own unique practices as to what they think works and how to handle cells and process them, Ang said. Our product will be regulated by the FDA, so we will be able to provide controls and the proper manufacturing steps to ensure were making the best quality product for patients.

The series B will push VOR33 into clinical trials in the first half of 2021, a target the companys on track to meet despite the COVID-19 pandemic. And Vor plans to expand its portfolio beyond CD33, starting with an umbrella of targets in the myeloid space, namely in acute myeloid leukemia, myelodysplastic syndromes and related diseases.

But we are also looking beyond that to other cancers where there are similar potentially biologically redundant targets we could pursue, said Ang, who took the companys helm in August 2019.

Since then, Vor has grown from a staff of six to 50, and its about to move into new digs in west Cambridge as it moves VOR33 toward the clinic. Its got the backing of RA Capital Management, Fidelity, 5AM Ventures, Johnson & Johnson Innovation, Osage University Partners, PureTech Health, the Pagliuca Family Office and Alexandria Venture Investments to do it all.

Read more from the original source:
Vor bags $110M to move engineered cell therapy into the clinic - FierceBiotech

Politicians Turn Their Backs on Public Safety and Will Want More of Your Money in November – City Watch

RANTZ & RAVEZ-Los Angeles Mayor Eric Garcetti (who called police officers killers) and City Councilmembers responded to the demands of protestors and rioters by slashing $150 million from the 2020-2021 LAPD budget.

LAs taxpaying residents and business owners were ignored by city officials who continue to permit the city to turn more neighborhoods into homeless camps with expanding decay and rising violent crime trends.

All but two voting councilmembers approved Garcettis 2020-2021 city budget which took $150 million from the LAPD and passed it to various organizations that serve minority communities in LA. Following the hatchet job on the LAPDs budget, the council adjourned, canceling future July meetings in order to go on a near month-long summer recess. This is happening while our City is on semi-lockdown due to the coronavirus that is spreading and infecting more people in the region and other American cities.

The FBI continues to investigate elected and appointed officials at City Hall, and two elected councilmembers have already been arrested; one has agreed to go to prison without a trial. A cloud of suspicion remains over the question of when the next arrest or arrests will occur as the investigation of illegal activity, bribes, and corruption continues to be conducted by FBI agents.

While members of the council enjoy their extended summer vacation and annual salary of over $207,000, the taxpayers of Los Angeles continue to struggle to find jobs, pay bills and find funds to repair the damages caused by the recent riots in large sections of the city. The lack of leadership and support displayed by the Mayor and Councilmembers for the LAPD and people of LA is truly a sad situation for Angelenos.

While the majority of the council voted to slash $150 million in public safety funds from the police budget, only two councilmembers had the courage to stand up to the anti-police groups calling for the financial reduction and redistribution to other causes. Councilmembers John Lee from the 12th District in the San Fernando Valley and Joe Buscaino from CD 15 in South Los Angeles and San Pedro. The rest of the council followed the lead of our spineless mayor and those pushing for the reduction in police funding. Keep this in mind when you call 911 in the future and there is a delay in the response time of officers.

Remember the names of the councilmembers who have turned their backs on public safety for all people in Los Angeles. Remember them when they ask you to vote for new tax increases which will appear on future ballots. Since they have turned their backs on public safety for you and your family, they might be better suited to find jobs in the private sector. I will remind you of those names this November and in future years. They do not deserve your votes.

On the subject of the November 3 election, let me share what Sacramento officials have in store for you and your wallets on the statewide ballot. There are currently 12 propositions that have qualified for the November election.

It is time to clean your guns and purchase fresh ammo. Be prepared to protect yourself and your family as we approach November and the state and national elections.

(Dennis P. Zine is a native of Los Angeles who retired from the LAPD after serving 33 years. Dennis remains an active Level 1 LAPD Reserve Officer. Dennis served for two years as the vice chairman on the Elected Los Angeles City Charter Reform Commission and was a member of the Los Angeles City Council for 12 years.) Edited for CityWatch by Linda Abrams.

Read the original:
Politicians Turn Their Backs on Public Safety and Will Want More of Your Money in November - City Watch

In the middle of pandemic, this young mom fights second cancer diagnosis – INFORUM

Two years ago, Bustos was happy. She was 20, recently married and had just found out she was pregnant with her first child. Taylor and her husband, Mark, 21, envisioned moving from Duluth to California and raising half a dozen kids. But those plans would have to wait.

Five months into her pregnancy, Bustos felt a lump on her neck. On Oct. 5, 2018, just a month after giving birth to her son, Solomon, she was diagnosed with nodular sclerosis classical Hodgkins lymphoma. Its the most common type of Hodgkins lymphoma, a cancer that affects the bodys immune system.

I was told, This is the good cancer, its curable, Bustos said. She underwent six months of chemotherapy at St. Lukes Radiation Oncology Associates in Duluth and was declared in remission in April 2019. After that, life went pretty much back to normal.

But last November, just before her first follow-up PET CT scan, Bustos prepared for the worst. A few weeks earlier, she had felt the lump in her neck return.

Soon later, she was back at St. Lukes, prepared to receive whatever news may come. Mark tossed a bright pink ball to Solomon to distract the boy and himself from the mounting anxiety as they waited for what felt like an eternity in the small examination room.

The young father was also trying to manage his stress from recently learning he was being laid off from his construction job. The doctor finally stepped in.

Taylor and Mark shared a kiss in their kitchen, taking any quiet moment they can to show their love to one another while raising a one-year-old. Taylor had been diagnosed with Hodgkin's Lymphoma only a month after giving birth to their first son, Solomon. She had just spent the better part of a year battling cancer and was now cancer free. So she was trying to enjoy any sense of normalcy she could. Alex Kormann / Minneapolis Star Tribune/TNS

Im sitting there with a one-year-old and my husband of two years and theyre telling me at 22 years old that I have cancer for the second time, Bustos said.

She had gone into the meeting with the mindset that she would never endure chemotherapy again. It was physically and mentally unlike any other suffering Ive ever gone through in my life and I didnt want to willingly say yes to going back there, Bustos said.

After a week of thinking and praying, Bustos stumbled across a Facebook post from a friend who had recently lost his father in a house fire. His words resonated so deeply with her that she decided she couldnt just lay down and die. This cancer could kill me, but dont I want my sweet son to know I tried? she said.

Once again, she went in for treatments, then slept for three days. The big difference this time was that, to make sure the cancer never came back, she was going to have to follow the doctors next recommendation.

On March 2, the Bustos family picked up and moved 200 miles across the state to Rochester for three months where she would undergo some of the most toxic chemotherapy available at the Mayo Clinic. The mix was so potent that she had to first undergo a stem cell collection; those stem cells would be transplanted afterward to regrow her immune system and other healthy cells decimated by the chemo.

Marks layoff, which at first seemed like a disaster, was now a gift. He could assume a larger role as the family caretaker. Some people might call that luck, but the Bustoss dont believe in luck. For them, it was an act of God.

When it came time to move, Taylors parents, Pam and Jerry, who live across the street from the Bustoses in Duluth, moved with them to help take care of Solomon and Taylor.

It really wasnt a difficult decision, said Jerry, who is a warehouse operator at a Duluth paper supply business.

For me, he said, I would do whatever it takes to get her healthy.

The whole family joined hands and prayed before dinner. God and faith are extremely important to them and has helped Taylor get through this difficult chapter in her life. The COVID-19 pandemic forced church to be held via live stream so Taylor was able to follow along even from 200 miles away. Her faith helped Taylor push through even the darkest moments of treatment. "Knowing I'm in the hands of such a faithful father made it peaceful," she said. Alex Kormann / Minneapolis Star Tribune/TNS

Their family squeezed as much as they could into their two cars, boxes stacked to the roof, rendering the rearview mirror useless. The family settled into a small house only a mile away from the Mayo Clinic.

Just over a week later, COVID-19 hit.

We knew Id have a weakened immune system and wed have to quarantine, Bustos said, but suddenly the whole world had to quarantine, too.

They stayed closely connected with their church through video chat and live streams. In solidarity, her entire family shaved their heads along with Bustos.

A little over a month after moving, Bustos prepared for her most difficult round of chemotherapy. All the effects of normal chemo, including nausea, exhaustion, loss of appetite and body pain would be amplified. And because of the coronavirus, she would be doing it alone. She packed her keyboard piano, a weeks worth of clothes, a few mementos from home and headed to the hospital. She would have to stay in a heavily filtered room by herself for a full week as she underwent treatment.

Masked nurses came and went as Bustos tried to picture what they looked like under all the PPE. Most days, she felt immensely lonely and sad. Originally, she was told shed be able to go home to see her family for one hour per day. The pandemic scrapped those plans. I would cry and nurses couldnt put their hand on my shoulder to tell me, Its OK, because of the coronavirus, Bustos said.

When she was finally able to return to her family a full week later, Bustos was ecstatic. To be able to be hugged was a very welcome relief from despair, she said.

She began to try and process what had happened to her over the last five months. She felt distant from and misunderstood by nearly everyone around her. It can look like its going well from the outside but when you literally want to die, the emotional side of things needs to be handled, she said.

Bustos has since begun therapy and is taking anti-depressants to help manage her mental pain.

As the family moved out of Rochester, the snow was gone. Birds chirped and flowers bloomed; a sign of rebirth and a new beginning.

When they pulled up in front of their apartment in Duluth, chalk drawings graced their sidewalk welcoming them home. Their front door was covered in balloons and a welcome banner was strung across the door frame, all put together by members of Bustoss church youth group.

Bustos collapsed on her old bed. She thought shed feel different in their own apartment, but it oddly felt the same. She had come to realize that home was no longer a physical space. Cancer changed that.

Home for me has become Mark and Solomon, she said, and so whether were in Rochester, Duluth or Timbuktu, Im home when Im with them.

2020 Star Tribune (Minneapolis)

Visit the Star Tribune (Minneapolis) at http://www.startribune.com

Distributed by Tribune Content Agency, LLC.

Read the original post:
In the middle of pandemic, this young mom fights second cancer diagnosis - INFORUM

Stem Cell Therapy Market to 2027 Global Analysis and Forecast by Type, Treatment, End User – Apsters News

Stem Cell Therapy Market Insights 2020

Increasing Awareness Related to the Stem Cells Therapy in Effective Disease Management

Stem cell research has been widely investigated globally to enhance human health in a medical setting. For this, creating public awareness about stem cell research is vital for realizing this potential. The stem cells main role is to replace dying cells and reconstruct damaged tissues. Based on the extensive stem cell research results, many scientists have claimed that the cells could probably generate cures and treatment for various diseases, including cancers, cardiovascular disease, and others. Newly developed stem cell therapies having the capability to replace disease, causing cells. Hence, patients now started relying on stem cell therapy that has long term positive outcomes. There is an increasing number of potential treatments that are undergoing in clinical trials phase. The FDA has approved very few stem cell therapies. For instance, in 2019, Fedratinib, approved by the FDA for the first-line treatment for fibrosis. Bone marrow transplantation is widely used stem cell based therapy. Blood forming stem cells were the first to be used in the clinic. This stem cell therapy has benefited thousands of patients who have leukemia.

Download sample PDF copy at:https://www.theinsightpartners.com/sample/TIPHE100000991/

Strategic Insights

Product launches and FDA approvals strategy is commonly adopted by companies to expand their footprint worldwide and meet the growing demand. This strategy is most commonly adopted by the market players in order to expand its product portfolio.

The market players operating in the stem cell therapy market adopt the strategy of collaborations to enlarge customer base across the world, which also permits the players to maintain their brand name globally.

Company Profiles

The stem cell therapy market is expected to grow, owing to factors such Increasing awareness related to the stem cells therapy in effective disease management, growing demand for regenerative medicines, and growing cancer prevalence across the globe are likely to have a positive impact on the growth of the market in coming years.

Purchase Copy of This Report at: https://www.theinsightpartners.com/buy/TIPHE100000991/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

Contact Us:

Call: +1-646-491-9876

Email: [emailprotected]

Continued here:
Stem Cell Therapy Market to 2027 Global Analysis and Forecast by Type, Treatment, End User - Apsters News

COVID-19 Update: Global Cancer Stem Cell Therapy Market is Expected to Grow at a Healthy CAGR with top players AVIVA BioSciences, AdnaGen, Advanced…

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Cancer Stem Cell TherapyMarket which would mention How the Covid-19 is Affecting the Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Key Regions and Proposal for Cancer Stem Cell Therapy Market Players to battle Covid-19 Impact.

Theglobal Cancer Stem Cell Therapy market has been remarkable momentum in the recent years. The Cancer Stem Cell TherapyMarket report is one of the most comprehensive and important data about business strategies, qualitative and quantitative analysis of Global Market. It offers detailed research and analysis of key aspects of the Cancer Stem Cell Therapy market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the Cancer Stem Cell Therapy market.

Top Leading players covered in the Cancer Stem Cell Therapy market report: AVIVA BioSciences, AdnaGen, Advanced Cell Diagnostics, Silicon Biosystems and More

Get PDF Sample Report With Impact of COVID-19 on Cancer Stem Cell Therapy [emailprotected] https://www.marketinforeports.com/Market-Reports/Request-Sample/98333

The Cancer Stem Cell Therapy market report specifically highlights the market share, regional outlook, company profiles, product portfolio, a record of the recent developments, strategic analysis, AVIVA BioSciences, AdnaGen, Advanced Cell Diagnostics, Silicon Biosystems in the market, sales, distribution chain, manufacturing, production, new market entrants as well as existing market players, advertising, brand value, popular products, demand and supply, and other important factors related to the market to help the new entrants understand the market scenario better. the global Cancer Stem Cell Therapy market will showcase a steady CAGR in the forecast year 2020 to 2026.

Market Segment by Type covers: Autologous Stem Cell Transplants Allogeneic Stem Cell Transplants Syngeneic Stem Cell Transplants Others

Market Segment by Application covers: Hospital Clinic Medical Research Institution Others

Our Complimentary Sample Cancer Stem Cell Therapy market Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology.

Inquire and Get Up to 30% DiscountBy Clicking Here! https://www.marketinforeports.com/Market-Reports/Request_discount/98333

Regions Covered in the Global Cancer Stem Cell Therapy Market: The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Years Considered to Estimate the Cancer Stem Cell Therapy Market Size: History Year: 2015-2019 Base Year: 2019 Estimated Year: 2020 Forecast Year: 2020-2026

Highlights of the Report: Accurate market size and CAGR forecasts for the period 2019-2026 Identification and in-depth assessment of growth opportunities in key segments and regions Detailed company profiling of top players of the global Cancer Stem Cell Therapy market Exhaustive research on innovation and other trends of the global Cancer Stem Cell Therapy market Reliable industry value chain and supply chain analysis Comprehensive analysis of important growth drivers, restraints, challenges, and growth prospects

For More Information:https://www.marketinforeports.com/Market-Reports/98333/Cancer-Stem-Cell-Therapy-market

Customization of the Report: Market Info Reports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Get Customization of the [emailprotected]: https://www.marketinforeports.com/Market-Reports/Request-Customization/98333/Cancer-Stem-Cell-Therapy-market

Contact Us: Mr. Marcus Kel Call: +1 415 658 9988 (International) +91 84 839 65921 (IND) Email: [emailprotected] Website: http://www.marketinforeports.com

Read more:
COVID-19 Update: Global Cancer Stem Cell Therapy Market is Expected to Grow at a Healthy CAGR with top players AVIVA BioSciences, AdnaGen, Advanced...